Abatacept

Red

Brand Name(s):Orencia

Indication:Rheumatoid arthritis, Juvenile idiopathic arthritis & Active psoriatic arthritis in adults

Rationale:1,2,8

Considered:Apr-09

Review Date:Jul-22

Comments:
NICE TA 375
Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed.
Full information can be found at:http://www.nice.org.uk/guidance/ta375/resources/adalimumab-etanercept-infliximab-certolizumab-pegol-golimumab-tocilizumab-and-abatacept-for-rheumatoid-arthritis-not-previously-treated-with-dmards-or-after-conventional-dmards-only-have-failed-82602790920133
January 2016 NICE technology appraisal guidance [TA373]